biolife solutions - BLFS
BLFS
Close Chg Chg %
21.15 0.74 3.50%
Closed Market
21.89
+0.74 (3.50%)
Volume: 606.90K
Last Updated:
Apr 22, 2025, 4:00 PM EDT
Company Overview: biolife solutions - BLFS
BLFS Key Data
| Open $21.66 | Day Range 21.45 - 22.73 |
| 52 Week Range 16.12 - 29.55 | Market Cap $1.00B |
| Shares Outstanding 47.50M | Public Float 45.58M |
| Beta 1.93 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.25 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 617.92K |
BLFS Performance
| 1 Week | -3.47% | ||
| 1 Month | -15.37% | ||
| 3 Months | -23.87% | ||
| 1 Year | 20.65% | ||
| 5 Years | 93.86% |
BLFS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About biolife solutions - BLFS
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.
BLFS At a Glance
BioLife Solutions, Inc.
3303 Monte Villa Parkway
Bothell, Washington 98021
| Phone | 1-425-402-1400 | Revenue | 82.25M | |
| Industry | Medical Specialties | Net Income | -36,061,000.00 | |
| Sector | Health Technology | Employees | 159 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BLFS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.539 |
| Price to Book Ratio | 3.49 |
| Price to Cash Flow Ratio | 141.846 |
| Enterprise Value to EBITDA | -684.671 |
| Enterprise Value to Sales | 13.634 |
| Total Debt to Enterprise Value | 0.027 |
BLFS Efficiency
| Revenue/Employee | 517,320.755 |
| Income Per Employee | -226,798.742 |
| Receivables Turnover | 8.972 |
| Total Asset Turnover | 0.201 |
BLFS Liquidity
| Current Ratio | 4.545 |
| Quick Ratio | 3.658 |
| Cash Ratio | 3.195 |
BLFS Profitability
| Gross Margin | 61.923 |
| Operating Margin | -8.667 |
| Pretax Margin | -13.89 |
| Net Margin | -43.841 |
| Return on Assets | -2.787 |
| Return on Equity | -3.317 |
| Return on Total Capital | -3.004 |
| Return on Invested Capital | -3.09 |
BLFS Capital Structure
| Total Debt to Total Equity | 8.648 |
| Total Debt to Total Capital | 7.96 |
| Total Debt to Total Assets | 7.462 |
| Long-Term Debt to Equity | 5.079 |
| Long-Term Debt to Total Capital | 4.674 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Biolife Solutions - BLFS
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 119.16M | 161.76M | 143.27M | 82.25M | |
Sales Growth
| +147.79% | +35.75% | -11.43% | -42.59% | |
Cost of Goods Sold (COGS) incl D&A
| 90.31M | 117.63M | 101.70M | 31.32M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 15.05M | 19.96M | 12.29M | 5.49M | |
Depreciation
| 6.85M | 10.26M | 7.11M | 2.75M | |
Amortization of Intangibles
| 8.20M | 9.70M | 5.18M | 2.74M | |
COGS Growth
| +281.39% | +30.26% | -13.55% | -69.20% | |
Gross Income
| 28.85M | 44.13M | 41.57M | 50.93M | |
Gross Income Growth
| +18.18% | +52.97% | -5.79% | +22.52% | |
Gross Profit Margin
| +24.21% | +27.28% | +29.02% | +61.92% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 58.27M | 84.04M | 99.10M | 58.06M | |
Research & Development
| 11.82M | 14.80M | 18.80M | 7.91M | |
Other SG&A
| 46.45M | 69.24M | 80.31M | 50.15M | |
SGA Growth
| +110.08% | +44.21% | +17.93% | -41.41% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (1.82M) | 104.93M | 13.29M | 4.07M | |
EBIT after Unusual Expense
| (27.61M) | (144.84M) | (70.83M) | (11.20M) | |
Non Operating Income/Expense
| 289.00K | 704.00K | 6.38M | 497.00K | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 432.00K | 687.00K | 1.81M | 719.00K | |
Interest Expense Growth
| - | +59.03% | +163.76% | -60.32% | |
Gross Interest Expense
| 432.00K | 687.00K | 1.81M | 719.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (27.75M) | (144.83M) | (66.26M) | (11.43M) | |
Pretax Income Growth
| -4,548.74% | -421.84% | +54.25% | +82.76% | |
Pretax Margin
| -23.29% | -89.53% | -46.25% | -13.89% | |
Income Tax
| (20.12M) | (5.02M) | 169.00K | (38.00K) | |
Income Tax - Current - Domestic
| - | 11.00K | 46.00K | 26.00K | |
Income Tax - Current - Foreign
| - | 9.00K | 205.00K | 185.00K | |
Income Tax - Deferred - Domestic
| (20.13M) | (5.24M) | (62.00K) | (64.00K) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (7.63M) | (139.81M) | (66.43M) | (11.39M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (7.63M) | (139.81M) | (66.43M) | (11.39M) | |
Net Income Growth
| -386.28% | -1,731.11% | +52.49% | +82.86% | |
Net Margin Growth
| -6.41% | -86.43% | -46.36% | -13.84% | |
Extraordinaries & Discontinued Operations
| - | - | - | (24.67M) | - |
Discontinued Operations
| - | - | - | (24.67M) | - |
Net Income After Extraordinaries
| (7.63M) | (139.81M) | (66.43M) | (36.06M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (7.63M) | (139.81M) | (66.43M) | (36.06M) | |
EPS (Basic)
| -0.1983 | -3.291 | -1.5194 | -0.7828 | |
EPS (Basic) Growth
| -321.07% | -1,559.61% | +53.83% | +48.48% | |
Basic Shares Outstanding
| 38.50M | 42.48M | 43.72M | 46.07M | |
EPS (Diluted)
| -0.1983 | -3.291 | -1.5194 | -0.7828 | |
EPS (Diluted) Growth
| -468.19% | -1,559.61% | +53.83% | +48.48% | |
Diluted Shares Outstanding
| 38.50M | 42.48M | 43.72M | 46.07M | |
EBITDA
| (14.37M) | (19.95M) | (45.24M) | (1.64M) | |
EBITDA Growth
| -681.24% | -38.83% | -126.70% | +96.38% | |
EBITDA Margin
| -12.06% | -12.34% | -31.58% | -1.99% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 31.333 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.04 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -0.119 | |
| Last Quarter’s Earnings | -0.04 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.25 | Next Fiscal Year Estimate | 0.115 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 6 | 7 | 4 |
| Mean Estimate | -0.04 | -0.02 | -0.12 | 0.12 |
| High Estimates | -0.01 | -0.01 | -0.02 | 0.15 |
| Low Estimate | -0.06 | -0.05 | -0.23 | 0.09 |
| Coefficient of Variance | -43.30 | -58.56 | -55.40 | 23.01 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 9 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Biolife Solutions - BLFS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Biolife Solutions - BLFS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 4, 2025 | Troy Wichterman Chief Financial Officer | 189,242 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.66 per share | 4,288,223.72 |
| Apr 4, 2025 | Sarah Aebersold Chief Human Resources Officer | 80,094 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.66 per share | 1,814,930.04 |
| Apr 4, 2025 | Karen Foster Chief Quality and Operations | 195,853 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.66 per share | 4,438,028.98 |
| Apr 4, 2025 | Aby J. Mathew EVP & Chief Scientific Officer | 309,576 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.66 per share | 7,014,992.16 |
| Apr 4, 2025 | Todd Berard Chief Marketing Officer | 135,956 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.66 per share | 3,080,762.96 |
| Mar 21, 2025 | Timothy L. Moore Director | 36,773 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Sarah Aebersold Chief Human Resources Officer | 85,865 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Catherine Havlik Coste Director | 5,701 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Karen Foster Chief Quality and Operations | 203,722 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Todd Berard Chief Marketing Officer | 144,858 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Tony J. Hunt Director | 6,876 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Troy Wichterman Chief Financial Officer | 214,929 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Aby J. Mathew EVP & Chief Scientific Officer | 320,165 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Sean Werner Chief Technology Officer | 27,784 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Rachel H. Ellingson Director | 49,825 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Amy DuRoss Director | 30,687 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Amy DuRoss Director | 23,811 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.96 per share | 594,322.56 |
| Mar 21, 2025 | Joydeep Goswami Director | 47,986 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Roderick de Greef President and CEO; Director | 527,793 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Sean Werner Chief Technology Officer | 4,865 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.03 per share | 116,905.95 |